An alternative synthesis of Vandetanib (Caprelsa™) via a microwave accelerated Dimroth rearrangement.
Loading...
Embargo End Date
ICR Authors
Authors
Brocklesby, KL
Waby, JS
Cawthorne, C
Smith, G
Waby, JS
Cawthorne, C
Smith, G
Document Type
Journal Article
Date
2017-04-12
Date Accepted
2017-02-27
Abstract
Vandetanib is an orally available tyrosine kinase inhibitor used in the treatment of cancer. The current synthesis proceeds via an unstable 4-chloroquinazoline, using harsh reagents, in addition to requiring sequential protection and deprotection steps. In the present work, use of the Dimroth rearrangement in the key quinazoline forming step enabled the synthesis of Vandetanib in nine steps (compared to the previously reported 12-14).
Citation
Tetrahedron letters, 2017, 58 (15), pp. 1467 - 1469
Source Title
Publisher
PERGAMON-ELSEVIER SCIENCE LTD
ISSN
0040-4039
eISSN
Collections
Research Team
PET Radiochemistry